Noscendo GmbH Revenue and Competitors
Estimated Revenue & Valuation
- Noscendo GmbH's estimated annual revenue is currently $9.8M per year.
- Noscendo GmbH's estimated revenue per employee is $155,000
Employee Data
- Noscendo GmbH has 63 Employees.
- Noscendo GmbH grew their employee count by 3% last year.
Noscendo GmbH's People
Name | Title | Email/Phone |
---|---|---|
1 | VP Marketing | Reveal Email/Phone |
2 | Chief Commercial Officer (CCO) | Reveal Email/Phone |
Noscendo GmbH Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Noscendo GmbH?
Noscendo GmbH, a Duisburg (Germany) based molecular diagnostics company, changes the way infection causative microbes are identified. Introducing a paradigm shift using proprietary algorithms and software harnessing next generation sequencing of cell free nucleic acids isolated from patient samples Noscendo brings the concept of liquid biopsy into the field of infectious diseases. Noscendo' s software solution is capable of differentiating infection from non-infectious signals and thereby aiding intensive care clinicians in their daily task to find the right decisions, enabling a targeted and successful treatment in an actionable timeframe.
keywords:N/AN/A
Total Funding
63
Number of Employees
$9.8M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | N/A | 103 | -1% | N/A |
#2 | N/A | 139 | 25% | N/A |
#3 | N/A | 193 | 19% | N/A |
#4 | $52.3M | 194 | 38% | N/A |
#5 | $82.6M | 229 | 20% | N/A |